Think of Inclisiran as a Niche Med for Lowering LDL

Inclisiran (Leqvio) will be the first "small interfering RNA" therapy for lowering cholesterol.

This injectable works at a different step in the same pathway as the PCSK9 inhibitors, alirocumab (Praluent) and evolocumab (Repatha).

Inclisiran prevents formation of the PCSK9 protein...alirocumab and evolocumab prevent PCSK9 binding.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote